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(age 18+). The current analysis was limited to respondents from
the UK. Individuals who reported having private health insur-
ance were 1:1 matched with those who did not on age, gender
and highest education level attained (college graduate vs. no
college). Paired t-tests were conducted to assess if any differences
existed for continuous variables. For dichotomous variables,
odds ratios were calculated to determine the likelihood of an
individual with health insurance experiencing comorbidities
compared to those without health insurance, and signiﬁcant dif-
ferences were tested using McNemar’s chi-square. RESULTS: Of
the 1944 respondents with private health insurance, 1925 were
matched to controls without health insurance yielding a 99%
match. Cases were generally healthier than controls. Cases had
higher SF-8 physical summary scores (49.73 vs 47.79, p < 0.001)
and SF-8 mental summary scores (49.72 vs 48.39, p < 0.001)
than controls. Cases had a signiﬁcantly decreased likelihood of
experiencing angina, COPD, heart attacks, over-active bladder,
abdominal bloating, anxiety, emphysema, depression, general-
ized anxiety disorder, pain, panic disorder and social anxiety
disorder. Cases experienced less activity impairment than con-
trols as measured by the Work Productivity and Activity Impair-
ment (WPAI) Questionnaire (19.18% vs. 25.12%, p < 0.001).
However, no signiﬁcant differences were noted for resource
utilization between those with and without private health insur-
ance. CONCLUSION: Unique characteristics differentiate those
with and without private health insurance in the UK. These
differences have ramiﬁcations for health policy and health care
spending.
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EUROPEAN PRICING AND REIMBURSEMENT UPDATE:
OPTIMAL MONETARY BENEFITS CAN DEPEND ON WHICH
COUNTRYTHE PROCESS IS INITIATED
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OBJECTIVES: To demonstrate that in European pricing and
reimbursement the beneﬁts of the pharmaceutical industries can
be optimised. METHODS: We have examined the reimburse-
ment criteria and drug price establishments of 12 European
countries: UK, The Netherlands, Germany, Sweden, Norway,
Belgium, Italy, Spain, France, Austria, Denmark and Switzerland.
Reimbursement systems were compared across six key reim-
bursement criteria (clinical efﬁcacy, cost effectiveness, budget
impact, foreign price reference, public medical need, value of
treatment) and classiﬁed into three categories whether a Cost
Effectiveness Analysis (CEA) is mandatory, optional or absent. In
parallel, two types of pricing system were identiﬁed: no pricing
reference and reference pricing. We have developed a network
model to demonstrate the relative monetary beneﬁts resulting
from the pricing and reimbursement systems behaviour.
RESULTS: We found that majority of countries determine drug
price before the reimbursement decision in order to perform a
CEA. However in other countries where CEA are optional or
absent, reimbursement decisions generally precede price negotia-
tions. The most important aspect of pricing for all countries
except Germany and UK is the price in other reference countries
(e.g. the price in France is the average of Spain, Italy, Germany
and UK drug prices). Therefore a higher price obtained in Spain
could increase the French drug price. Other countries (like
Belgium or Italy) set price according to speciﬁc country. Prag-
matically each country has its own ﬁxed budget allocated to
different diseases; therefore a reimbursement and price determi-
nation across Europe should be approached strategically to opti-
mise margins and beneﬁts. CONCLUSION: The applications of
CEA for decision making have progressed in European countries
constraining prices and costs to effectiveness. Nevertheless, in
other countries drug prices are more sensitive to public health
and are negotiated with public authorities. A European national
pricing and reimbursement approach by disease network model
could generate optimal monetary beneﬁt for the pharmaceutical
industry.
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OBJECTIVES: The purpose of the study was to compare and
contrast reference pricing with health technology assessment
(HTA) as alternative strategies for obtaining value for money
from pharmaceuticals. METHODS: The study focussed on
decisions about the initial price and reimbursement status of
innovative drugs. Four countries were studied: Germany, The
Netherlands, Sweden and the UK. These countries have operated
one, or both, of the two policies at certain points in time,
sometimes in parallel. Drugs in four groups were considered:
cholesterol-lowering agents, insulin analogues, biologics for
rheumatoid arthritis and atypicals for schizophrenia. RESULTS:
Where reference pricing schemes were in operation, all the drugs
obtained reimbursement. In addition, all the drugs in the same
group were placed in the same cluster. Prices were also similar,
with the exception of cholesterol-lowering agents, where some
generic agents were available. Where technology assessments had
been performed, the use of some drugs (e.g. insulin analogues)
was restricted more than the licensed indication. On occasions,
technology assessments were used to assess whether a premium
price was justiﬁed for a given product. CONCLUSION: Com-
pared with HTA, reference pricing is a relatively blunt instrument
for obtaining value for money from pharmaceuticals. It may have
a role alongside HTA, in making reimbursement decisions about
those drugs which, because of resource constraints, cannot be
subjected to a technology assessment.
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OBJECTIVES: The new Single Technology Appraisal (STA)
process introduced by NICE attempts to shorten the process of
assessment. The purpose of this study was to review, summarise
and critique all of the STAs published to date and to analyse
themes and trends. METHODS: A database was developed to
collate key data from the STAs completed to date with an initial
focus on oncology submissions. Clinical and economic data as
well as summaries of all key comments were extracted from the
manufacturer submission, evidence review group report, expert
submission and the ﬁnal appraisal determination. Data were then
analysed for associations between ICER values, clinical and eco-
nomic evidence and submission outcome. RESULTS: Since the
introduction of the STA process, six STAs have been completed
for drugs in oncology. A further 27 STAs are in development,
with 10 more in oncology. Three out of the six oncology sub-
missions were considered to have resulted in positive guidance
from NICE, recommending the use of the drug in the NHS.
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Reasons for negative guidance included uncertainties in the clini-
cal evidence presented; and lack of a robust economic argument.
Completed industry submissions in oncology presented ICERs
ranging from 4,726 to 30,100. The corresponding ERG
group estimates of ICERs ranged from 4,726 to 86,770. The
ERG’s criticisms of the industry submissions included omission
of a systematic review, failure to use recommended approaches to
evidence synthesis and failure to adhere to the reference case.
CONCLUSION: The single technology appraisal process is in its
infancy with contributors gaining valuable experience with each
new appraisal. Acknowledging and acting upon the criticism
from ERGs will help improve the quality, and possibly the out-
comes of future STAs. Reviewing completed STAs and analysing
trends and themes may inform future strategic and tactical plan-
ning of submissions.
PHP34
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OBJECTIVES: To assess existing incentives for indication sub-
grouping in NICE reimbursement submissions using a simple
probabilistic model. The model allows for uncertainty and makes
explicit assumptions regarding market size, price, subgrouping,
cost-effectiveness, market share and reimbursement acceptance.
METHODS: The Ofﬁce of Fair Trading in the UK has recently
recommended reform of the UK Pharmaceutical Price Regulation
Scheme from proﬁt limitation to one of value-based pricing. It
has been debated whether such a move would encourage the
targeting of cost-effective subgroups, or whether further incen-
tives would help the UK National Health Service receive a greater
share of net health beneﬁt. We have extended an existing proba-
bilistic model of manufacturer pricing decisions to encompass a
continuum of patient cost-effectiveness. Uncertainty can be incor-
porated at the patient and market level. A revenue probability
distribution function was derived as a function of price. With this
model, we explored the incentives that already exist for the
targeting of cost-effective subpopulations using a probabilistic
assessment of risks to product revenue streams. We calculated the
revenue probability density function under a range of subgroup-
ing scenarios assuming the drug is priced such that, over the
whole indicated population, the ICER is £30,000 per QALY.
RESULTS: We produced summary statistics from the probability
density functions indicative of the level of risk to the product
revenue available to the manufacturer, dependent on a number of
assumptions. In an example, targeting 20%, 80% and 100% of
an indicated population produced expected annual revenues of
£16.0 m, £51.7 m and £14.1 m respectively. Probabilities of gen-
erating revenues exceeding £15 m were 91%, 80% and 17%
respectively. CONCLUSION: The revenue probability distribu-
tion function provides a useful tool to guide pharmaceutical
pricing decisions, according to a company’s risk proﬁle. With
rational, probabilistic assessment of risk to product revenue
streams, it can be shown that incentives already exist for indica-
tion subgrouping.
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OBJECTIVES: To investigate doctors’ prescribing behavior in
Greece. METHODS: Data was derived from a closed question-
naire applied to a random stratiﬁed sample consisting of 1463
doctors. The response rate was 82.3%. Analysis of categorical
data concerned the calculation of descriptive measures, frequen-
cies and relative frequencies, and test of independence using
Chi-square test. RESULTS: Drugs’ effectiveness, appearance of
side effects and drug cost for the patient has been shown the most
important criteria for prescription. Younger and less experienced
doctors seem to take more into account drug cost, dosage and
side effects. Scientiﬁc journals, medical conferences and literature
review are referred as the main information sources about drug’s
effectiveness. As less signiﬁcant sources of inﬂuence are men-
tioned the sales’ representatives of pharmaceutical companies
and the internet. It is revealed that sales’ representatives of phar-
maceutical companies don’t affect physicians’ prescription deci-
sion, due to the fact that they believe that the information sales’
representatives of pharmaceutical companies provide, focuses
mainly in drugs’ advantages. Regarding the internet use it seems
that Greek doctors, mainly the older ones, are not familiar with
the use of new technologies and they prefer printed information
from journals and literature. Furthermore, it is mentioned that
any attempt of reforming drugs’ reimbursement policy doesn’t
affect the volume and the cost of prescribing. In general, physi-
cians have a positive opinion about generics, even though only
3.6% prescribes generics frequently. Male doctors tend to pre-
scribe generics more often. The majority of doctor’s believe that
the price of new drugs is too high compared to their improved
effectiveness. CONCLUSION: Knowledge of the proﬁle prescrip-
tion of doctors could be a useful tool for supply—side drug
policy interventions. Such studies combined with patients
reported outcomes could contribute to the qualitative and quan-
titative evaluation of drugs’ policy.
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OBJECTIVES: RTR is a regional telemedicine network allowing
consultancy between local and university hospitals located in
Toulouse. RTR offers tele-consultations and distance training for
practitioners located in isolated zones of access. This communi-
cation between different centres allows a better decision-making
regarding the necessity of transferring patients to university hos-
pitals. This study is a further step to the telemedicine tariffs study.
To evaluate the health insurance savings associated with RTR
network. METHODS: A pool of neurosurgery patients for
whom telemedicine consultation led to released or avoided trans-
fer was identiﬁed. The rate of modiﬁed transfer decisions due to
teleconsultations was derived from patients’ ﬁles. IN all, 240
patients’ ﬁles of neurosurgery were analysed but only 172 pro-
vided the information on initial needs of transfer. 58 out of those
172 ﬁles corresponded to avoided transfers. Hospitalisation asso-
ciated costs were identiﬁed from DRGs’ tariffs. Practitioners
clariﬁed the main diagnosis what allowed to identify the corre-
sponding DRG’s. Costs related to patients’ medical transfers
(such as the use of helicopters or ambulances) to university
hospitals were also computed. In order to assess the global RTR’s
impact, results observed from exploitable ﬁles have been
extrapolated to the whole population (240 patients). RESULTS:
For the 172 informed ﬁles, hospitalization cost savings:
EUR198,643; transportation cost savings: EUR172,533. In
2005, Telemedicine consultation led to a total savings of
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